Prof. Dr. CAVİT BOZ

Yayın Ağı

Makaleler 189

1. Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish families

Büyükgöl F., GÜRDAMAR B., Aluçlu M. U., Beckmann Y., BİLGÜVAR K., BOZ C., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

2. Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

Pirmani A., De Brouwer E., Arany Á., Oldenhof M., Passemiers A., Faes A., et al.

npj Digital Medicine , cilt.8, sa.1, 2025 (SCI-Expanded, Scopus)

3. Disease course after pregnancy in women with progressive multiple sclerosis symptoms

Shipley J., Beadnall H. N., Sanfilippo P. G., Horakova D., BOZ C., Prat A., et al.

Multiple Sclerosis Journal , cilt.31, sa.12, ss.1439-1451, 2025 (SCI-Expanded, Scopus)

4. Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

Jokubaitis V. G., Alroughani R., Altintas A., Eichau S., Hughes S., Willekens B., et al.

Multiple Sclerosis Journal , cilt.31, sa.9, ss.1088-1101, 2025 (SCI-Expanded, Scopus)

5. Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study

Siriratnam P., Huda S., Van der Walt A., Sanfilippo P., Sharmin S., Foong Y. C., et al.

Journal of neurology , cilt.272, sa.5, ss.339, 2025 (SCI-Expanded, Scopus)

6. Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Foong Y. C., Merlo D., Gresle M., Buzzard K., Horakova D., Havrdova E. K., et al.

Journal of Neurology, Neurosurgery and Psychiatry , 2025 (SCI-Expanded, Scopus)

7. Persistent progression independent of relapse activity in multiple sclerosis

Zhu C., Zhou Z., Kalincik T., Roos I., Buzzard K., Skibina O., et al.

Brain Communications , cilt.7, sa.5, 2025 (ESCI, Scopus)

8. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

Dekeyser C., Hautekeete M., Cambron M., Van Pesch V., Patti F., Kuhle J., et al.

Journal of Neurology, Neurosurgery and Psychiatry , sa.11, ss.1021-1031, 2024 (SCI-Expanded, Scopus)

9. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies

Yeh W. Z., van der Walt A., Skibina O. G., Kalincik T., Alroughani R., Kermode A. G., et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION , cilt.11, sa.6, 2024 (SCI-Expanded, Scopus)

10. Determination of important predictors for the fifth-year Expanded Disability Status Scale scores of patients with multiple sclerosis using machine learning

Buçan Kırkbir İ., Kurt B., Boz C., Terzi M.

Turkish Journal of Neurology , cilt.30, sa.3, ss.157-166, 2024 (ESCI, Scopus, TRDizin)

11. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Roos I., Sharmin S., Malpas C., Ozakbas S., Lechner-Scott J., Hodgkinson S., et al.

Multiple Sclerosis Journal , cilt.30, sa.9, ss.1163-1175, 2024 (SCI-Expanded, Scopus)

12. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

Foong Y. C., Merlo D., Gresle M., Buzzard K., Zhong M., Yeh W. Z., et al.

Journal of Neurology, Neurosurgery and Psychiatry , cilt.95, sa.8, ss.767-774, 2024 (SCI-Expanded, Scopus)

13. Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein

KOÇ S., ŞEN S., TERZİ Y., KIZILAY F., DEMİR S., AKSOY D. B., et al.

Balkan Medical Journal , cilt.41, sa.4, ss.272-279, 2024 (SCI-Expanded, Scopus, TRDizin)

14. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , cilt.94, sa.12, ss.1004-1011, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

15. Risk of secondary progressive multiple sclerosis after early worsening of disability

Dzau W., Sharmin S., Patti F., Izquierdo G., Eichau S., Prat A., et al.

Journal of Neurology, Neurosurgery and Psychiatry , cilt.94, sa.12, ss.984-991, 2023 (SCI-Expanded, Scopus)

16. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sánchez M. M., Ozakbas S., et al.

Brain : a journal of neurology , cilt.146, sa.11, ss.4633-4644, 2023 (SCI-Expanded, Scopus)

17. Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting

Altunan B., Ünal A., EFENDİ H., Köseoğlu M., Terzi M., Kotan D., et al.

Multiple Sclerosis and Related Disorders , cilt.77, 2023 (SCI-Expanded, Scopus)

18. Disability accrual in primary and secondary progressive multiple sclerosis

Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., et al.

Journal of Neurology, Neurosurgery and Psychiatry , cilt.94, sa.9, ss.707-717, 2023 (SCI-Expanded, Scopus)

19. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?

Tütüncü M., Demir S., Arslan G., Dinç Ö., Şen S., GÜNDÜZ T., et al.

Multiple Sclerosis and Related Disorders , cilt.75, 2023 (SCI-Expanded, Scopus)

20. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis

BOZ C., ÖZAKBAŞ S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., et al.

Neurological Sciences , cilt.44, sa.6, ss.2121-2129, 2023 (SCI-Expanded, Scopus)

21. Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment

Terzi M., Helvaci E. M., Şen S., BOZ C., Çilingir V., Akçali A., et al.

Noropsikiyatri Arsivi , cilt.60, sa.1, ss.23-27, 2023 (SCI-Expanded, Scopus, TRDizin)

22. External validation of a clinical prediction model in multiple sclerosis

Moradi N., Sharmin S., Malpas C. B., Shaygannejad V., Terzi M., BOZ C., et al.

Multiple Sclerosis Journal , cilt.29, sa.2, ss.261-269, 2023 (SCI-Expanded, Scopus)

23. Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)

Tuncer A., Kürtüncü M., Terzi M., UYGUNOĞLU U., Göncüoğlu C., Yüceyar A. N., et al.

Turkish Journal of Medical Sciences , cilt.53, sa.1, ss.323-332, 2023 (SCI-Expanded, Scopus, TRDizin)

24. The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis

Şen S., Arslan G., Tütüncü M., Demir S., Dinç Ö., GÜNDÜZ T., et al.

Noropsikiyatri Arsivi , cilt.60, sa.3, ss.252-256, 2023 (SCI-Expanded, Scopus, TRDizin)

25. Clinical course and outcome of Covid-19 in patients with myasthenia gravis

Aktoz G., BOZ C., Zengin S., Okumus A. C., Horozoglu H., KARA F., et al.

Neurological Research , cilt.45, sa.6, ss.583-589, 2023 (SCI-Expanded, Scopus)

26. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis

Usta N. C., BOZ C., Terzi M.

Clinical Neurology and Neurosurgery , cilt.224, 2023 (SCI-Expanded, Scopus)

27. Evaluation of clinical features and prognosis of myasthenia gravis in adults based on the age of onset: A retrospective study from a single center of 30 years MG registry

KARA F., GÖL M. F., BOZ C.

Neurology Asia , cilt.27, sa.4, ss.981-989, 2022 (SCI-Expanded, Scopus)

28. Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION , cilt.9, sa.6, 2022 (SCI-Expanded, Scopus)

29. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., ÖZAKBAŞ S., et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , cilt.93, ss.1330-1337, 2022 (SCI-Expanded, Scopus)

30. Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., et al.

Multiple Sclerosis and Related Disorders , cilt.66, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

31. Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

Kalincik T., Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.28, sa.11, ss.1752-1761, 2022 (SCI-Expanded, Scopus)

32. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al.

NEUROLOGY , cilt.99, sa.17, 2022 (SCI-Expanded, Scopus)

33. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry

Sharmin S., Malpas C. B., Roos I., Diouf I., Alroughani R., ÖZAKBAŞ S., et al.

Journal of Neurology, Neurosurgery and Psychiatry , cilt.93, sa.12, ss.1322-1329, 2022 (SCI-Expanded, Scopus)

34. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., et al.

EUROPEAN JOURNAL OF NEUROLOGY , cilt.29, sa.8, ss.2321-2334, 2022 (SCI-Expanded, Scopus)

35. Disease activity during pregnancy and postpartum in women with MS receiving ocrelizumab in a real-world cohort

Yeh W., Van der Walt A., Kermode A., Kalincik T., Alroughani R., Lechner-Scott J., et al.

EUROPEAN JOURNAL OF NEUROLOGY , cilt.29, ss.295-296, 2022 (SCI-Expanded, Scopus)

36. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study

Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.

NEUROLOGY , cilt.98, sa.24, 2022 (SCI-Expanded, Scopus)

37. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Lefort M., Sharmin S., Andersen J. B., Vukusic S., Casey R., Debouverie M., et al.

BMC MEDICAL RESEARCH METHODOLOGY , cilt.22, sa.1, 2022 (SCI-Expanded, Scopus)

38. Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Zhong M., van der Walt A., Stankovich J., Kalincik T., Buzzard K., Skibina O., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.28, sa.6, ss.958-969, 2022 (SCI-Expanded, Scopus)

39. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., et al.

PharmacoEconomics , cilt.40, sa.3, ss.323-339, 2022 (SCI-Expanded, SSCI, Scopus)

40. Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey

Usta N. C., Kartal S., Gunay B. O., BOZ C.

Asian Biomedicine , cilt.16, sa.1, ss.23-30, 2022 (SCI-Expanded, Scopus)

41. Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression

Sevim S., DEMİRKIRAN D. M., Terzi M., YÜCEYAR A. N., Tasdelen B., Idiman E., et al.

ARQUIVOS DE NEURO-PSIQUIATRIA , cilt.80, ss.168-172, 2022 (SCI-Expanded, Scopus)

42. EFFECTS OF RITUXIMAB ON PROGNOSIS IN MYASTHENIA GRAVIS: A SINGLE-CENTER EXPERIENCE FROM TURKEY

GÖL M. F., KARA F., BOZ M., MUTLU A., Karakullukçu S., BOZ C.

Ideggyogyaszati Szemle , cilt.75, sa.9-10, ss.351-359, 2022 (SCI-Expanded, Scopus)

43. Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study

Bekircan-Kurt C. E., Inan B., Bulut O., Sengun I., KARLI H. N., Gunes N., et al.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY , cilt.58, sa.4, ss.257-260, 2021 (SCI-Expanded, Scopus, TRDizin)

44. A Case Report of Acute Disseminated Encephalomyelitis in a Pregnant Woman After COVID-19 Infection

KIZILIRMAK R., ÖZALP M., OSMANAĞAOĞLU M. A., BOZ C.

TURK NOROLOJI DERGISI , cilt.27, ss.49-51, 2021 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma

45. Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

Kenney R., Liu M., Patil S., Alroughani R., Ampapa R., Bergamaschi R., et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES , cilt.430, 2021 (SCI-Expanded, Scopus)

46. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E. K., et al.

CNS DRUGS , cilt.35, sa.11, ss.1217-1232, 2021 (SCI-Expanded, Scopus)

47. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018

Moradi N., Sharmin S., Malpas C., ÖZAKBAŞ S., Shaygannejad V., Terzi M., et al.

CNS DRUGS , cilt.35, sa.10, ss.1097-1106, 2021 (SCI-Expanded, Scopus)

48. Determinants of therapeutic lag in multiple sclerosis

Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.27, sa.12, ss.1838-1851, 2021 (SCI-Expanded, Scopus)

49. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

De Brouwer E., Becker T., Moreau Y., Havrdova E. K., Trojano M., Eichau S., et al.

COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE , cilt.208, 2021 (SCI-Expanded, Scopus)

50. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sorensen P. S., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.53, 2021 (SCI-Expanded, Scopus)

51. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

Yeh W. Z., Widyastuti P. A., Van der Walt A., Stankovich J., Havrdova E., Horakova D., et al.

NEUROLOGY , cilt.96, sa.24, 2021 (SCI-Expanded, Scopus)

52. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

Minh Le M. L., Malpas C., Sharmin S., Horakova D., Havrdova E., Trojano M., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.27, sa.5, ss.755-766, 2021 (SCI-Expanded, Scopus)

53. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

Kunchok A., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.27, sa.5, ss.695-705, 2021 (SCI-Expanded, Scopus)

54. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Kalincik T., Diouf I., Sharmin S., Malpas C., Spelman T., Horakova D., et al.

NEUROLOGY , cilt.96, sa.5, 2021 (SCI-Expanded, Scopus)

55. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.

NEUROLOGY , cilt.96, sa.2, 2021 (SCI-Expanded, Scopus)

56. Determinants of disability development in patients with multiple sclerosis

KARA F., GÖL M. F., BOZ C.

ARQUIVOS DE NEURO-PSIQUIATRIA , cilt.79, sa.6, ss.489-496, 2021 (SCI-Expanded, Scopus)

57. The Role of Thrombo-inflammatory Biomarkers in the Prognosis of Cere-bral Venous Sinus Thrombosis

Karahan S. Z., GAZİOĞLU S., DİLAVER İ., BOZ C.

CURRENT NEUROVASCULAR RESEARCH , cilt.18, sa.2, ss.237-243, 2021 (SCI-Expanded, Scopus)

58. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study

Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.

NEUROIMAGE-CLINICAL , cilt.32, 2021 (SCI-Expanded, Scopus)

59. Genotype phenotype correlation of cadasil patients-single center experience

ÇEBİ A. H., BOZ C.

Annals of Medical Research , cilt.28, sa.02, ss.381-384, 2021 (TRDizin)

60. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis

Lizak N., Malpas C. B., Sharmin S., Havrdova E. K., Horakova D., Izquierdo G., et al.

JAMA NEUROLOGY , cilt.77, sa.11, ss.1398-1407, 2020 (SCI-Expanded, Scopus)

61. Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse Methylprednisolone

Karahan S. Z., BOZ C., Terzi M., Aktoz G., Sen S., Ozbudun B., et al.

CLINICAL NEUROLOGY AND NEUROSURGERY , cilt.197, 2020 (SCI-Expanded, Scopus)

62. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.

BRAIN , cilt.143, ss.2742-2756, 2020 (SCI-Expanded, Scopus)

63. Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant database

Tunca C., Seker T., Akcimen F., Coskun C., Bayraktar E., Palvadeau R., et al.

HUMAN MUTATION , cilt.41, sa.8, 2020 (SCI-Expanded, Scopus)

64. 'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'

Sevim S., DEMİRKIRAN D. M., Terzi M., YÜCEYAR A. N., Tasdelen B., Idiman E., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.42, 2020 (SCI-Expanded, Scopus)

65. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review

AlSharoqi I. A., Aljumah M., Bohlega S., BOZ C., Daif A., El-Koussa S., et al.

NEUROLOGY AND THERAPY , cilt.9, sa.1, ss.55-66, 2020 (SCI-Expanded, ESCI, Scopus)

66. The COVID-19 from Neurological Overview

ACAR T., ACIMAN DEMİREL E., AFŞAR FAK N. E. Y., AKÇALI A., AKMAN DEMİR G., ALAGÖZ A. N., et al.

Turkish Journal Of Neurology , cilt.26, sa.2, ss.58-108, 2020 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma

67. Nöro-Behçet Hastalığında Klinik Özellikler

Gazioğlu S., Boz M., Aksu Arıca D., Boz C.

Dicle Tıp Dergisi , cilt.47, sa.2, ss.324-330, 2020 (TRDizin)

68. Early clinical markers of aggressive multiple sclerosis

Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.

BRAIN , cilt.143, ss.1400-1413, 2020 (SCI-Expanded, Scopus)

69. Decreased second to fourth digit ratios in female multiple sclerosis patients

GAZİOĞLU S., ALKAN İ., KARAMAN A. G., BOZ C.

EARLY HUMAN DEVELOPMENT , cilt.144, 2020 (SCI-Expanded, Scopus)

70. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder

Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZİ M., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.38, 2020 (SCI-Expanded, Scopus)

71. Electrophysiological, functional and histopathological assessments of high dose melatonin on regeneration after blunt sciatic nerve injury

Yazar U., Çakır E., Boz C., Çobanoğlu Ü., Baykal S.

JOURNAL OF CLINICAL NEUROSCIENCE , cilt.72, ss.370-377, 2020 (SCI-Expanded, Scopus)

72. Risk of secondary progressive multiple sclerosis: A longitudinal study

Fambiatos A., Jokubaitis V., Horakova D., Havrdova E. K., Trojano M., Prat A., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.26, sa.1, ss.79-90, 2020 (SCI-Expanded, Scopus)

73. A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

Akman Demir G., Turkoglu R., Saip S., Yuceyar N., EFENDİ H., TURAN Ö. F., et al.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY , cilt.56, sa.4, ss.253-257, 2019 (SCI-Expanded, Scopus, TRDizin)

74. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis

BOZ C., TERZİ M., Ozer B., Turkoglu R., KARABUDAK R., EFENDİ H., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.36, 2019 (SCI-Expanded, Scopus)

75. International consensus on quality standards for brain health-focused care in multiple sclerosis

Hobart J., Bowen A., Pepper G., Crofts H., Eberhard L., Berger T., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.25, sa.13, ss.1809-1818, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

76. The Efficacy of Acupuncture in the Treatment of Bell's Palsy Sequelae

Ertemoğlu Öksüz C., Kalaycioglu A., Uzun Ö., Kalkışım Ş. N., Zihni N. B., Yildirim A., et al.

JOURNAL OF ACUPUNCTURE AND MERIDIAN STUDIES , cilt.12, sa.4, ss.122-130, 2019 (ESCI, Scopus)

77. Susac Syndrome: Clinical characteristics, diagnostic findings and treatment in 19 cases

Karahan S. Z., Boz C., Saip S., Kale N., Demirkaya S., Celik Y., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.33, ss.94-99, 2019 (SCI-Expanded, Scopus)

78. The efficacy of acupuncture in the treatment of Bell’xxs palsy sequelae

ERTEMOĞLU ÖKSÜZ C., KALAYCIOĞLU A., UZUN Ö., KALKIŞIM Ş. N., ZİHNİ N. B., Yıldırım A., et al.

JOURNAL OF ACUPUNCTURE AND MERIDIAN STUDIES , 2019 (Scopus)

79. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , cilt.90, sa.4, ss.458-468, 2019 (SCI-Expanded, Scopus)

80. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

Nguyen A., Havrdova E. K., Horakova D., Izquierdo G., Kalincik T., van der Walt A., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.28, ss.235-243, 2019 (SCI-Expanded, Scopus)

81. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION , cilt.321, sa.2, ss.175-187, 2019 (SCI-Expanded, Scopus)

82. Clinical and morphometric examination of acupuncture effect in Bell's palsy sequelae

Oksuz C., Kalaycioglu A., Yildirim A., Uzun Ö., Kalkışım Ş. N., Zihni N. B., et al.

CUKUROVA MEDICAL JOURNAL , cilt.44, ss.11-19, 2019 (ESCI, TRDizin)

83. Pediatrik Yaş Başlangıçlı Multipl Skleroz ile Erişkin Yaş Başlangıçlı Multipl Sklerozun Karşılaştırılması

DİLBER B., DİLER DURGUT B., ACAR ARSLAN E., ŞAHİN S., CANSU A., BOZ C., et al.

TURKİYE KLİNİKLERİ JOURNAL OF NEUROLOGY , 2019 (TRDizin)

84. A rare metabolic disease: cerebrotendinous xanthomatosis

Kamaşak T., Demirhan Y. N., Parıltan Küçükalioğlu B., Boz C., Çebi A. H., Eyüboğlu İ., et al.

Van Medical Journal , cilt.26, sa.2, ss.265-267, 2019 (TRDizin)

85. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

Hughes J., Jokubaitis V., Lugaresi A., Hupperts R., Izquierdo G., Prat A., et al.

JAMA NEUROLOGY , cilt.75, sa.11, ss.1407-1415, 2018 (SCI-Expanded, Scopus)

86. Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis

Min M., Spelman T., Lugaresi A., BOZ C., Spitaleri D. L. A., Pucci E., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.24, sa.12, ss.1569-1577, 2018 (SCI-Expanded, Scopus)

87. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Kister I., Spelman T., Patti F., Duquette P., Trojano M., Izquierdo G., et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES , cilt.391, ss.72-76, 2018 (SCI-Expanded, Scopus)

88. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis

BOZ C., TERZİ M., Karahan S. Z., Sen S., Sarac Y., Mavis M. E.

MULTIPLE SCLEROSIS JOURNAL , cilt.24, sa.9, ss.1205-1211, 2018 (SCI-Expanded, Scopus)

89. Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]

Fragoso Y. D., Brooks J. B. B., Spelman T., BOZ C., Alroughani R., Lugaresi A., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.22, ss.166, 2018 (SCI-Expanded, Scopus)

90. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

Signori A., Izquierdo G., Lugaresi A., Hupperts R., Grand'Maison F., Sola P., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.24, sa.5, ss.642-652, 2018 (SCI-Expanded, Scopus)

91. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Kappos L., Bar-Or A., Cree B. A. C., Fox R. J., Giovannoni G., Gold R., et al.

The Lancet , cilt.391, sa.10127, ss.1263-1273, 2018 (SCI-Expanded, Scopus)

92. Pregnancy-induced Susac Syndrome: A Case Report

Usta N. C., BOZ C., Ozmenoglu M.

TURKISH JOURNAL OF NEUROLOGY , cilt.24, sa.1, ss.70-71, 2018 (ESCI, Scopus, TRDizin)

93. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Fragoso Y. D., Spelman T., BOZ C., Alroughani R., Lugaresi A., Vucic S., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.19, ss.105-108, 2018 (SCI-Expanded, Scopus)

94. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

Howard J. F., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., et al.

LANCET NEUROLOGY , cilt.16, sa.12, ss.976-986, 2017 (SCI-Expanded)

95. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

Lorscheider J., Jokubaitis V. G., Spelman T., Izquierdo G., Lugaresi A., Havrdova E., et al.

NEUROLOGY , cilt.89, sa.10, ss.1050-1059, 2017 (SCI-Expanded, Scopus)

96. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Kalincik T., Manouchehrinia A., Sobisek L., Jokubaitis V., Spelman T., Horakova D., et al.

BRAIN , cilt.140, ss.2426-2443, 2017 (SCI-Expanded, Scopus)

97. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

Spelman T., Meyniel C., Ignacio Rojas J., Lugaresi A., Izquierdo G., Grand'Maison F., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.23, sa.10, ss.1346-1357, 2017 (SCI-Expanded, Scopus)

98. Prognostic Indicators in Pediatric Clinically Isolated Syndrome

Iaffaldano P., Simone M., Lucisano G., Ghezzi A., Coniglio G., Morra V. B., et al.

ANNALS OF NEUROLOGY , cilt.81, sa.5, ss.729-739, 2017 (SCI-Expanded, Scopus)

99. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Kalincik T., Brown J. W. L., Robertson N., Willis M., Scolding N., Rice C. M., et al.

LANCET NEUROLOGY , cilt.16, sa.4, ss.271-281, 2017 (SCI-Expanded, Scopus)

100. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Lizak N., Lugaresi A., Alroughani R., Lechner-Scott J., Slee M., Havrdova E., et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , cilt.88, sa.3, ss.196-203, 2017 (SCI-Expanded, Scopus)

101. Contribution of different relapse phenotypes to disability in multiple sclerosis

Stewart T., Spelman T., Havrdova E., Horakova D., Trojano M., Izquierdo G., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.23, sa.2, ss.266-276, 2017 (SCI-Expanded, Scopus)

102. A Comparison of Pediatric- and Adult-Onset Multiple Sclerosis

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., et al.

Turkiye Klinikleri Journal of Neurology , cilt.12, sa.3, ss.57-63, 2017 (TRDizin)

103. Pediatrik Yaş Başlangıçlı Multipl Skleroz ileErişkin Yaş Başlangıçlı Multipl SklerozunKarşılaştırılmasıA Comparison of Pediatric- and Adult-Onset Multiple Sclerosis

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., et al.

Turkiye Klinikleri Journal of Neurology , cilt.12, sa.3, ss.57-63, 2017 (TRDizin)

104. Defining secondary progressive multiple sclerosis

Lorscheider J., Buzzard K., Jokubaitis V., Spelman T., Havrdova E., Horakova D., et al.

BRAIN , cilt.139, ss.2395-2405, 2016 (SCI-Expanded, Scopus)

105. Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis

Jokubaitis V. G., Spelman T., Kalincik T., Lorscheider J., Havrdova E., Horakova D., et al.

ANNALS OF NEUROLOGY , cilt.80, sa.1, ss.89-100, 2016 (SCI-Expanded, Scopus)

106. Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS

Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., Wiendl H., et al.

NEUROLOGY-CLINICAL PRACTICE , cilt.6, sa.2, ss.102-115, 2016 (ESCI, Scopus)

107. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Warrender-Sparkes M., Spelman T., Izquierdo G., Trojano M., Lugaresi A., Grand'Maison F., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.22, sa.4, ss.520-532, 2016 (SCI-Expanded, Scopus)

108. Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis

Karahan S. Z., BOZ C., Kilic S., Usta N. C., Ozmenoglu M., ALTUNAYOĞLU ÇAKMAK V., et al.

MULTIPLE SCLEROSIS INTERNATIONAL , cilt.2016, 2016 (ESCI) Sürdürülebilir Kalkınma

109. Demiyelizan Hastalıklar ve Önlenebilir Acil Durumlar

ALTIPARMAK D., BOZ C.

türkiye klinikleri , 2016 (TRDizin)

110. Defining reliable disability outcomes in multiple sclerosis

Kalincik T., CUTTER G., Spelman T., Jokubaitis V., HAVRDOVA E., HORAKOVA D., et al.

BRAIN , cilt.138, 2015 (SCI-Expanded, Scopus)

111. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Features

Altintas A., KARABUDAK R., Balci B. P., TERZİ M., Soysal A., Saip S., et al.

NEUROLOGIST , cilt.20, sa.4, ss.61-66, 2015 (SCI-Expanded, Scopus)

112. Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

Rojas J. I., Patrucco L., Trojano M., Lugaresi A., Izquierdo G., Butzkueven H., et al.

Multiple Sclerosis Journal - Experimental, Translational and Clinical , cilt.1, 2015 (Scopus)

113. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Kalincik T., Jokubaitis V., IZQUIERDO G., DUQUETTE P., GIRARD M., Grammond P., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.21, sa.9, ss.1159-1171, 2015 (SCI-Expanded, Scopus)

114. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

Ribbons K. A., McElduff P., BOZ C., Trojano M., Izquierdo G., Duquette P., et al.

PLOS ONE , cilt.10, sa.6, 2015 (SCI-Expanded, Scopus)

115. BREMSO: a simple score to predict early the natural course of multiple sclerosis

BERGAMASCHI R., MONTOMOLI C., MALLUCCI G., LUGARESI A., IZQUIERDO G., GRAND'MAISON F., et al.

EUROPEAN JOURNAL OF NEUROLOGY , cilt.22, sa.6, ss.981-989, 2015 (SCI-Expanded, Scopus)

116. Predictors of disability worsening in clinically isolated syndrome

Jokubaitis V. G., Spelman T., Kalincik T., Izquierdo G., Grand'Maison F., Duquette P., et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY , cilt.2, sa.5, ss.479-491, 2015 (SCI-Expanded, Scopus)

117. Patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder: Turkish Multicenter Data

Altintas A., Karabudak R., Balci B. P., Terzi M., Soysal A., SAİP S., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.21, sa.6, ss.824-825, 2015 (SCI-Expanded, Scopus)

118. Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., et al.

ANNALS OF NEUROLOGY , cilt.77, sa.3, ss.425-435, 2015 (SCI-Expanded, Scopus)

119. Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent

Spelman T., Gray O., Trojano M., Petersen T., Izquierdo G., Lugaresi A., et al.

ANNALS OF NEUROLOGY , cilt.76, sa.6, ss.880-890, 2014 (SCI-Expanded, Scopus)

120. Risk of relapse phenotype recurrence in multiple sclerosis

KALINCIK T., BUZZARD K., Jokubaitis V., TROJANO M., DUQUETTE P., IZQUIERDO G., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.20, sa.11, ss.1511-1522, 2014 (SCI-Expanded, Scopus)

121. Evaluation of Temperament and Character Features as Risk Factors for Depressive Symptoms in Patients with Restless Legs Syndrome

Cakmak V., GAZİOĞLU S., USTA N. C., Ozkorumak E., AYAR A., TOPBAŞ M., et al.

JOURNAL OF CLINICAL NEUROLOGY , cilt.10, sa.4, ss.320-327, 2014 (SCI-Expanded, Scopus)

122. Factors associated with early hospital arrival in acute ischemic stroke patients

KOKSAL E. K., GAZİOĞLU S., BOZ C., ÇAN G., ALİOĞLU Z.

NEUROLOGICAL SCIENCES , cilt.35, sa.10, ss.1567-1572, 2014 (SCI-Expanded, Scopus)

123. Predictors and dynamics of postpartum relapses in women with multiple sclerosis

HUGHES S. E., SPELMAN T., GRAY O. M., BOZ C., TROJANO M., LUGARESI A., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.20, sa.6, ss.739-746, 2014 (SCI-Expanded, Scopus)

124. Personality Traits of Patients With Multiple Sclerosis and Their Relationship With Clinical Characteristics

GAZİOĞLU S., Cakmak V. A., Ozkorumak E., USTA N. C., Ates C., BOZ C.

JOURNAL OF NERVOUS AND MENTAL DISEASE , cilt.202, sa.5, ss.408-411, 2014 (SCI-Expanded, SSCI, Scopus)

125. Fingolimod after natalizumab and the risk of short-term relapse

Jokubaitis V. G., Li V., Kalincik T., Izquierdo G., Hodgkinson S., Alroughani R., et al.

NEUROLOGY , cilt.82, sa.14, ss.1204-1211, 2014 (SCI-Expanded, Scopus)

126. Anomalik İnnervasyonlar

GAZİOĞLU S., BOZ C.

ürkiye Klinikleri Nöroloji Özel Dergisi- Elektromiyografi (EMG) Özel Sayısı , sa.6, ss.24-30, 2014 (Hakemli Dergi)

127. Anti John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey

MEFKURE E., AĞAN K., AK F., ANLAR Ö., BALCI F. B., BOZ C., et al.

Journal of experimental and clinical Medicine , cilt.31, ss.31-36, 2014 (Hakemli Dergi)

128. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

Kalincik T., VIVEK V., Jokubaitis V., LECHNER-SCOTT J., TROJANO M., IZQUIERDO G., et al.

BRAIN , cilt.136, ss.3609-3617, 2013 (SCI-Expanded, Scopus)

129. Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study

Iuliano G., BOZ C., Cristiano E., Duquette P., Lugaresi A., Oreja-Guevara C., et al.

JOURNAL OF NEUROLOGY , cilt.260, sa.5, ss.1258-1262, 2013 (SCI-Expanded, Scopus)

130. Fluctuations of MS births and UV-light exposure

VERHEUL F., SMOLDERS J., TROJANO M., LEPORE V., ZWANIKKEN C., AMATO M. P., et al.

ACTA NEUROLOGICA SCANDINAVICA , cilt.127, sa.5, ss.301-308, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

131. Clinical Characteristics and Prognosis of Guillain Barre Syndrome

GAZİOĞLU S., TOMAK T., BOZ C.

JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH , cilt.30, sa.1, ss.124-134, 2013 (SCI-Expanded, Scopus, TRDizin)

132. Cerebral venous thrombosis after high dose steroid in multiple sclerosis: a case report

GAZİOĞLU S., SOLMAZ D., BOZ C.

HIPPOKRATIA , cilt.17, sa.1, ss.88-90, 2013 (SCI-Expanded, Scopus)

133. Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis

Trojano M., Lucchese G., Graziano G., Taylor B. V., Simpson S., Lepore V., et al.

PLOS ONE , cilt.7, sa.10, 2012 (SCI-Expanded, Scopus)

134. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study

ALTINTAŞ A. T., PETEK B., ISIK N., Terzi M., BOLUKBASI F., TAVSANLI M., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.18, sa.10, ss.1448-1453, 2012 (SCI-Expanded, Scopus)

135. Ocular and cervical vestibular evoked myogenic potentials in multiple sclerosis patients

GAZİOĞLU S., BOZ C.

CLINICAL NEUROPHYSIOLOGY , cilt.123, sa.9, ss.1872-1879, 2012 (SCI-Expanded, Scopus)

136. Magnetic resonance imaging in bilateral brachial neuritis with pure sensory involvement

GAZİOĞLU S., BOZ C., SARI A.

NEUROLOGICAL SCIENCES , cilt.33, sa.4, ss.927-930, 2012 (SCI-Expanded, Scopus)

137. Increasing age at disability milestones among MS patients in the MSBase Registry

Kister I., CHAMOT E., CUTTER G., Bacon T. E., JOKUBAITIS V. G., HUGHES S. E., et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES , cilt.318, ss.94-99, 2012 (SCI-Expanded, Scopus)

138. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude

LECHNER-SCOTT J., SPENCER B., DE MALMANCHE T., Attia J., Fitzgerald M., TROJANO M., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.18, sa.7, ss.974-982, 2012 (SCI-Expanded, Scopus)

139. Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome

MEYNIEL C., SPELMAN T., JOKUBAITIS V. G., TROJANO M., IZQUIERDO G., GRAND'MAISON F., et al.

PLOS ONE , cilt.7, sa.6, 2012 (SCI-Expanded, Scopus)

140. Cervical vestibular evoked myogenic potentials to air-conducted sound in early amyotrophic lateral sclerosis

KILIC S., GAZİOĞLU S., ZENGIN K. S., DUBUS H. U., BOZ C.

NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY , cilt.42, sa.3, ss.119-123, 2012 (SCI-Expanded, Scopus)

141. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry

Hughes S., Spelman T., Trojano M., Lugaresi A., Izquierdo G., Grand'Maison F., et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , cilt.83, sa.3, ss.305-310, 2012 (SCI-Expanded, Scopus)

142. Basilar artery occlusion in migraine-like headache: a possible triggering effect of sumatriptan

GAZİOĞLU S., BOZ C., Ozmenoglu M.

NEUROLOGICAL SCIENCES , cilt.33, sa.1, ss.125-128, 2012 (SCI-Expanded, Scopus)

143. The effect of pregnancy on relapse rate and disability progression in MS: results from the MSBase Registry

Hughes S. E., Spelman T., Gray O. M., Boz C., Trojano M., Zwanikken C., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.17, 2011 (SCI-Expanded, Scopus)

144. Ultra-annual changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicentre study

Iuliano G., Boz C., Cristiano E., Duquette P., Lugaresi A., Van Pesch V.

MULTIPLE SCLEROSIS JOURNAL , cilt.17, 2011 (SCI-Expanded, Scopus)

145. Electrodiagnosis of carpal tunnel syndrome in patients with diabetic polyneuropathy

GAZİOĞLU S., BOZ C., CAKMAK V. A.

CLINICAL NEUROPHYSIOLOGY , cilt.122, sa.7, ss.1463-1469, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

146. VEMP responses are not affected in non-insulin-dependent diabetes mellitus patients with or without polyneuropathy

BEKTAS D., GAZİOĞLU S., ARSLAN S., COBANOGLU B., BOZ C., CAYLAN R.

ACTA OTO-LARYNGOLOGICA , cilt.128, sa.7, ss.768-771, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

147. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

Boz C., OGER J., GIBBS E., GROSSBERG S. E.

MULTIPLE SCLEROSIS , cilt.13, sa.9, ss.1127-1137, 2007 (SCI-Expanded, Scopus)

148. Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache

Boz C., Gazioglu S., ALTUNAYOGLU V., HOCAOGLU C.

PSYCHIATRY AND CLINICAL NEUROSCIENCES , cilt.61, sa.5, ss.534-542, 2007 (SCI-Expanded, Scopus)

149. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in multiple sclerosis

Boz C.

CLINICAL NEUROLOGY AND NEUROSURGERY , cilt.108, sa.6, ss.618, 2006 (SCI-Expanded, Scopus)

150. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy

Kister I., Gulati S., Boz C., Bergamaschi R., Piccolo G., Oger J., et al.

ARCHIVES OF NEUROLOGY , cilt.63, sa.6, ss.851-856, 2006 (SCI-Expanded, Scopus)

151. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta

Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., et al.

Clinical Neurology and Neurosurgery , cilt.108, sa.2, ss.124-128, 2006 (SCI-Expanded, Scopus)

152. The impact of migraine on epilepsy: a prospective prognosis study

Velioglu S., Boz C., Ozmenoglu M.

CEPHALALGIA , cilt.25, sa.7, ss.528-535, 2005 (SCI-Expanded, Scopus)

153. Temperament and character profiles of patients with tension-type headache and migraine

Boz C., Velioglu S., Ozmenoglu M., Sayar K., Alioglu Z., Yalman B., et al.

PSYCHIATRY AND CLINICAL NEUROSCIENCES , cilt.58, sa.5, ss.536-543, 2004 (SCI-Expanded, Scopus)

154. Individual risk factors for carpal tunnel syndrome: an evaluation of body mass index, wrist index and hand anthropometric measurements

Boz C., Ozmenoglu M., Altunayoglu V., Velioglu S., Alioglu Z.

CLINICAL NEUROLOGY AND NEUROSURGERY , cilt.106, sa.4, ss.294-299, 2004 (SCI-Expanded, Scopus)

155. The efficacy and safety of dipyrone (Novalgin®) tablets in the treatment of acute migraine attacks: A double-blind, cross-over, randomized, placebo-controlled, multi-center study

Tulunay F. C., ERGÜN H., Gülmez S. E., Özbenli T., Özmenoǧlu M., Boz C., et al.

Functional Neurology , cilt.19, sa.3, ss.197-202, 2004 (SCI-Expanded, Scopus)

156. The efficacy and safety of dipyrone (Novalgin (R)) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study

Tulunay F., Ergun H., Gulmez S., Ozbenli T., Ozmenoglu M., Boz C., et al.

FUNCTIONAL NEUROLOGY , cilt.19, sa.3, ss.197-202, 2004 (SCI-Expanded, Scopus)

157. Guillain-Barre syndrome during treatment with interferon alpha for hepatitis B

BOZ C., OZMENOGLU M., AKTOZ G., VELIOGLU S., Alioglu Z.

JOURNAL OF CLINICAL NEUROSCIENCE , cilt.11, sa.5, ss.523-525, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

158. Transient Tic disorder following carbon monoxide poisoning

Alioglu Z., BOZ C., SARI A., AYNACI M.

JOURNAL OF NEURORADIOLOGY , cilt.31, sa.3, ss.231-233, 2004 (SCI-Expanded, Scopus)

159. Ocular myasthenia gravis associated with X-linked recessive spinal and bulbar muscular atrophy

Boz C., Kalay E., Sahin N., VELİOĞLU S., Ozmenoglu M., Karagüzel A.

Journal of Clinical Neuromuscular Disease , cilt.5, sa.3, ss.115-118, 2004 (Scopus)

160. Kronik gerilim tipi baş ağrılı hastalarda mizaç ve karakter profili

BOZ C., Sayar K., VELIOGLU S., Hocaoğlu Ç., ALİOĞLU Z., YALMAN B., et al.

Türk Psikiyatri Derg. , cilt.15, sa.2, ss.105-111, 2004 (SCI-Expanded, TRDizin)

161. Benign acute childhood myositis

SONMEZ F., CAKIR M., YAYLA S., Boz C.

MEDICAL PRINCIPLES AND PRACTICE , cilt.13, sa.4, ss.227-229, 2004 (SCI-Expanded, Scopus)

162. Local cold effect on the excitability recovery curve of the sympathetic skin response

BOZ C., ÖZMENOĞLU M., ALİOĞLU Z., VELİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S.

electromyography and clinical neurophysiology , 2004 (Hakemli Dergi)

163. Temperament and character profile of patients with chronic tension-type headache Kronik Gerilim Tipi Baş Agrili Hastalarda Mizaç ve Karakter Profili.

BOZ C., Sayar K., VELİOĞLU S., HOCAOĞLU Ç., ALİOĞLU Z., Yalman B., et al.

Türk psikiyatri dergisi = Turkish journal of psychiatry , cilt.15, sa.2, ss.105-111, 2004 (SCI-Expanded, Scopus, TRDizin)

164. Isolated hypoglossal nerve palsy in a child

AYNACI F., SEN Y., Boz C., ORHAN F.

TURKISH JOURNAL OF PEDIATRICS , cilt.46, sa.1, ss.101-103, 2004 (SCI-Expanded, Scopus)

165. Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients

BOZ C., Altunayoglu V., VELİOĞLU S., Ozmenoglu M.

Journal of Headache and Pain , cilt.4, sa.2, ss.72-78, 2003 (SCI-Expanded, Scopus)

166. Tissue plasminogen activator mass concentration in ischemic acute stroke patients

BOZ C., AKBAS A., ALİOĞLU Z., OZMENOGLU M.

Turkish Journal of Medical Sciences , cilt.33, sa.3, ss.155-159, 2003 (Scopus, TRDizin)

167. Gebelik ve loğusalıkta akut strok olayları

ALİOĞLU Z., ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M.

Türk Serebrovasküler Hastalıklar Dergisi , cilt.9, sa.2, ss.63-66, 2003 (TRDizin)

168. Central nervous system involvement in autoimmune polyglandular syndrome

Boz C., Velioglu S., Altunayoglu V., Ozmenoglu M., Erem C.

CLINICAL NEUROLOGY AND NEUROSURGERY , cilt.105, sa.2, ss.102-104, 2003 (SCI-Expanded, Scopus)

169. Plasma homocysteine in acute and subacute phases after ischemic stroke İskemi̇k strok'ta akut ve subakut dönem homosi̇stei̇ n düzeyleri̇

VELİOĞLU S., BOZ C., Ari N., Uydu H. A., Özmenoǧlu M.

Turk Beyin Damar Hastaliklar Dergisi , cilt.9, sa.1, ss.1-5, 2003 (Scopus, TRDizin)

170. Acute disseminated encephalomyelitis after bee sting

Boz C., Velioglu S., Omenoglu M.

NEUROLOGICAL SCIENCES , cilt.23, sa.6, ss.313-315, 2003 (SCI-Expanded, Scopus)

171. Diyabetik Nöropati

GAZİOĞLU S., BOZ C.

Galenos Tıp Dergisi , ss.24-35, 2003 (Hakemli Dergi) Sürdürülebilir Kalkınma

172. Epilepsili hastalarda kognitif fonksiyonların olaya ilişkin endojen potansiyellerle (P300) değerlendirilmesi

BOZ C., VELIOGLU S., ALİOĞLU Z., OZMENOGLU M.

TÜRK NÖROLOJİ DERGİSİ , cilt.1, ss.53-61, 2003 (ESCI, Scopus, TRDizin)

173. X-linked spinal and bulbar muscular atrophy without proximal atrophy

Boz C., Sahin N., Kalay E., Velioglu S., Ozmenoglu M.

CLINICAL NEUROLOGY AND NEUROSURGERY , cilt.105, sa.1, ss.14-17, 2002 (SCI-Expanded, Scopus)

174. Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment

Agelink M., Boz C., Ullrich H., Andrich J.

PSYCHIATRY RESEARCH , cilt.113, sa.1-2, ss.139-149, 2002 (SCI-Expanded, SSCI, Scopus)

175. Treatment of intractable hiccups Dirençli hiçkiriklarda tedavi

BOZ C., VELİOĞLU S., Özmenoǧlu M.

SENDROM , cilt.14, sa.12, ss.70-73, 2002 (Scopus)

176. Fatal brainstem infarction after apheresis donation.

BOZ C., VELİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ALİOĞLU Z., ÖZMENOĞLU M.

JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH , cilt.19, sa.3, ss.1-9, 2002 (TRDizin)

177. Fatal brainstem infarction after apheresis donation

BOZ C., VELIOGLU S., Altunayoğlu Çakmak V., ALİOĞLU Z., OZMENOGLU M.

e-Journal of Neurological Sciences - Turkish , cilt.19, sa.3, ss.35-50, 2002 (SCI-Expanded, Scopus, TRDizin)

178. Non-ketojenik hiperglisemiye bağlı hemibalismus-hemikore ve kraniyal magnetik rezonans görüntüleme

ALİOĞLU Z., BOZ C., OZMENOGLU M.

Parkinson Hastalığı ve Hareket Bozuklukları Dergisi , cilt.5, sa.2, ss.62-66, 2002 (Hakemsiz Dergi)

179. Evaluation of plasma endothelin-1 levels in patients with cerebral infarction

Alioglu Z., OREM A., BULBUL I., BOZ C., OZMENOGLU M., VANIZOR B.

ANGIOLOGY , cilt.53, sa.1, ss.77-82, 2002 (SCI-Expanded, Scopus)

180. Eklamptik ve preeklamptik olgularda elektroensefalografi ve kraniyal magnetik rezonans görüntüleme bulguları

ALİOĞLU Z., VELIOGLU S., Dinç G., BOZ C., DINC H., OZMENOGLU M.

EPILEPSY , cilt.1, ss.21-25, 2002 (Scopus)

181. The Effects of Pentoxifylline in Experimental Nerve Injury

BAYKAL S., BOZ C., ÇAKIR E., BAYTAN Ş. H., KARAKUŞ M., KUZEYLİ K.

TURKISH JOURNAL OF MEDICAL SCIENCES , sa.32, ss.207-210, 2002 (Scopus, TRDizin)

182. Baclofen is effective in intractable hiccups induced by brainstem lesions

Boz C., Velioglu S., Bulbul I., Ozmenoglu M.

NEUROLOGICAL SCIENCES , cilt.22, sa.5, ss.409, 2001 (SCI-Expanded, Scopus)

183. Status epilepticus after stroke

VELIOGLU S., OZMENOGLU M., BOZ C., Alioglu Z.

STROKE , cilt.32, sa.5, ss.1169-1172, 2001 (SCI-Expanded, Scopus)

184. Cerebral infarction following intravenous immunoglobulin therapy for Guillain-Barre syndrome

VELİOĞLU S., Özmenoǧlu M., BOZ C.

Journal of Stroke and Cerebrovascular Diseases , cilt.10, sa.6, ss.290-292, 2001 (SCI-Expanded, Scopus)

185. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage

ALIOGLU Z., Bülbül İ., ÖREM A., OZMENOGLU M., KURAL B., BOZ C.

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES , cilt.9, sa.4, ss.176-180, 2000 (Scopus)

186. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage

ALIOGLU Z., Bülbül İ., ÖREM A., OZMENOGLU M., KURAL B., BOZ C.

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES , cilt.9, sa.4, ss.176-180, 2000 (Scopus)

187. Serebrovasküler hastalık sonrası gelişen epilepsi nöbetleri.

VELİOĞLU S., BOZ C., ALİOĞLU Z., OZMENOGLU M., Yalman B.

TÜRK NÖROLOJİ DERGİSİ , cilt.6, sa.4, ss.39-45, 2000 (ESCI, Scopus, TRDizin)

188. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage

ALİOĞLU Z., BULBUL I., OREM A., OZMENOGLU M., VANIZOR B., BOZ C.

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES , cilt.9, ss.176-180, 2000 (SCI-Expanded, Scopus)

189. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage

ALİOĞLU Z., Bülbül I., ÖREM A., Özmenoǧlu M., KURAL B., BOZ C.

Journal of Stroke and Cerebrovascular Diseases , cilt.9, sa.4, ss.176-180, 2000 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 184

1. Real-world experience with Cladribine (Mavenclad) in the MSBase registry

Butzkueven H., Spelman T., Van der Walt A., Hodgkinson S., Ozakbas S., Alroughani R., et al.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, ss.364-365, (Özet Bildiri)

2. Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years

Roberts J., Sharmin S., Horakova D., Havrdova E., Ozakbas S., Lugaresi A., et al.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, ss.357-360, (Özet Bildiri)

3. MULTİPL SKLEROZ TEDAVİSİNDE DİMETİL FUMARATIN İKİ YILLIK TÜRKİYE GERÇEK YAŞAM VERİSİ

TERZİ M., ŞEN S., BECKMANN Y., KARABUDAK R., HELVACI E. M., YETKİN M. F., et al.

59.Ulusal Nöroloji Kongresi, Antalya, Türkiye, 13 - 18 Aralık 2023, (Özet Bildiri)

4. The Effect of Pregnancy on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Associated Disease Activity and Progression: A Multi-center Retrospective Study from Turkey

Uzunkopru C., Şen S., Altintas A., ÇAKAN ERCAN M., BÜNÜL S. D., Demir G. A., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.664, (Özet Bildiri)

5. AN UNUSUAL REASON OF BACK PAIN AND WEAKNESS: SPINAL CORD INFARCTION

CANDAŞ K. B., KURŞUN S., GÜL K., YÜKSEL Z. Ö., İMAMOĞLU M., ÖZER V., et al.

17th WINFOCUS WORLD CONGRESS & 8th EURASIAN CONGRESS ON EMERGENCY MEDICINE, Türkiye, 1 - 04 Aralık 2022, (Özet Bildiri)

6. GEBELİĞİN NÖROMYELİTİS OPTİKA SPEKTRUM HASTALIĞI (NMOSD) VE MYELİN OLİGODENDROSİT GLİKOPROTEİN İLİŞKİLİ HASTALIK (MOGAD) PROGNOZU ÜZERİNE ETKİLER

UZUNKÖPRÜ C., GÜNDÜZ T., BOZ C., GÜLER S.

58. Ulusal Nöroloji Kongresi (Uluslararası Katılımlı), Antalya, Türkiye, 19 Kasım 2022, (Tam Metin Bildiri)

7. Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study

Butzkueven H., Spelman T., ÖZAKBAŞ S., Laureys G., Van Hijfte L., Alroughani R., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.384-386, (Özet Bildiri)

8. Emulating randomized clinical trials in relapsing-remitting multiple sclerosis with nonrandomized real-world evidence: an application using data from the MSBase registry

Ponzano M., ÖZAKBAŞ S., Horakova D., Havrdova E., Terzi M., Alroughani R., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.379-380, (Özet Bildiri)

9. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sanchez M. M., ÖZAKBAŞ S., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.967-970, (Özet Bildiri)

10. Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS

Kalincik T., Sharman S., Roos I., Freedman M., Atkins H., Burman J., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.11-14, (Özet Bildiri)

11. A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis

Roos I., Hughes S., MacDonnell G., Boz C., Alroughani R., Ozakbas S., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.951-953, (Özet Bildiri)

12. Medulla oblongata volume measured from clinical routine T2-FLAIR scans is associated with disability progression in a multiple sclerosis real-world dataset

Bergsland N., Barnett M., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.289-290, (Özet Bildiri)

13. Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Zhu C., Kalincik T., Horakova D., Zhen Z., Buzzard K., Skibina O., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.645-647, (Özet Bildiri)

14. Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi-National Registry (P17-4.001)

Kalincik T. K., TERZİ M., TÜRKOĞLU R., BOZ C., ALTINTAŞ A., Malpas C. B. M., et al.

American Academy of Neurology, Seattle, Amerika Birleşik Devletleri, 20 Mayıs 2022, cilt.98, ss.17, (Tam Metin Bildiri)

15. Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis

Spelman T., Acosta C., Hyde R., Campbell N., Havrdova E., Horakova D., et al.

8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 - 13 Eylül 2020, cilt.26, ss.526-527, (Özet Bildiri)

16. Distal Tübüler Asidoz, Osteopetrozis ve Serebral Kalsifikasyonu Olan Bir Vaka,?

KAYNAR R. K., BOZ C., ULUSOY Ş., ÖZMENOĞLU M., Gül S.

4. Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi,, Antalya, Türkiye, ss.56, (Tam Metin Bildiri)

17. Distal Tübüler Asidoz, Osteopetrozis ve Serebral Kalsifikasyonu Olan Bir Vaka,?

KAYNAR R. K., BOZ C., ULUSOY Ş., ÖZMENOĞLU M., Gül S.

4. Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi,, Antalya, Türkiye, ss.56, (Tam Metin Bildiri)

18. Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis

Kalincik T., Ibrahima D., Malpas C., Horakova D., Havrdova E., Trojano M., et al.

Annual Meeting of the American-Academy-of-Neurology, Toronto, Kanada, 25 Nisan - 01 Mayıs 2020, (Özet Bildiri)

19. Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)

Sharmin S., Bovis F., Malpas C. B., Horakova D., Trojana M., BOZ C., et al.

American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 26 Nisan 2020, cilt.94, ss.2002, (Tam Metin Bildiri)

20. Identification of Therapeutic Lag in Multiple Sclerosis (1787)

Roos I., Leray E., Frascoli F., Horakova D., Trojana M., ÖZAKBAŞ S., et al.

American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 19 Nisan 2020, cilt.94, ss.1787, (Tam Metin Bildiri)

21. Identification of Therapeutic Lag in Multiple Sclerosis

ROOS I., Leray E., FRASCOLİ F., Casey R., Horakova D., Havrdova E., et al.

Annual Meeting of the American-Academy-of-Neurology, Toronto, Kanada, 25 Şubat - 01 Mart 2020, (Özet Bildiri)

22. Determinants of Therapeutic Lag in Multiple Sclerosis (2059)

Roos I., Leray E., Frascoli F., Horakova D., Trojano M., Patti F., et al.

American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 27 Nisan 2020, cilt.94, ss.2059, (Tam Metin Bildiri)

23. of Therapeutic Lag in Relapsing Multiple Sclerosis

ROOS I., FRASCOLİ F., Horakova D., Havrdova E., Trojano M., Izquierdo G., et al.

Conference of MS-Research-Australia, 31 Ekim - 01 Kasım 2019, (Özet Bildiri)

24. Multipl Skleroz Hastalarında Fingolimod Tedavisinin Etkililiği : Türkiye Gerçek Yaşam Verileri

TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., EKMEKÇİ Ö., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri)

25. SS-78 GEÇ VE ERKEN BAŞLANGIÇLI MULTİPLE SKLEROZHASTALARINDA, KLİNİK VE HASTALIK PROGRESYONUFARKLILIKLARI

ZENGIN KARAHAN S., bilgiç a. b., KARAMAN A. G., BOZ C., TERZİ M.

55. Ulusal Nöroloji Kongresi, Türkiye, 15 - 21 Kasım 2019, (Tam Metin Bildiri)

26. SS-46 OCRELİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİLERİ:3 MULTİPL SKLEROZ MERKEZİNİN TECRÜBELERİ

VURAL E., TERZİ M., Sunter G., AĞAN YILDIRIM K., BOZ C.

55. Ulusal Nöroloji Kongresi, Türkiye, 15 Kasım 2018 - 21 Kasım 2019, (Tam Metin Bildiri)

27. BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS): YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLE SKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLI BESLENME VE FİZİKSEL AKTİVİTE DURUMUNUN ARAŞTIRILMASI

YÜCEYAR A. N., AKMAN DEMİR G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., et al.

55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri) Sürdürülebilir Kalkınma

28. TEP-147 MULTİPL SKLEROZ HASTALARINDA FİNGOLİMODTEDAVİSİNİN ETKİLİLİĞİ : TÜRKİYE GERÇEK YAŞAMVERİLERİ (REFINE)

TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., Ekmekci Ö., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 16 - 20 Kasım 2019, ss.276, (Özet Bildiri)

29. SS-77 BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS):YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLESKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLIBESLENME VE FİZİKSEL AKTİVİTE DURUMUNUNARAŞTIRILMASI

YÜCEYAR A. N., AKMAN G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 16 - 20 Kasım 2019, ss.45, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

30. Self-management and coping strategies in patients with multipl sclerosia multicenter -prospective study

BOZ C., ÜNAL A., AKÇALI A., ALTUNRENDE B.

ECTRIMS, 11 - 13 Eylül 2019, (Özet Bildiri)

31. Real-world experience with Ocrelizumab in the MSBase Registry

Butzkueven H., Spelman T., Patti F., Ozakbas S., Eichau S., Alroughani R., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.539-540, (Özet Bildiri)

32. Modifiers of the effectiveness of MS immunotherapies

Kalincik T., Malpas C., Sharmin S., Horakova D., Havrdova E. K., Trojano M., et al.

33. Determinants of therapeutic lag in relapsing multiple sclerosis

Roos I., Frascoli F., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., et al.

34. Real-life outcomes of Ocrelizumab treatment from 3 multiple sclerosis centers in Turkey

Vural E., Terzi M., Sunter G., Gunal D., Agan K., Boz C.

35. MS cohorts and treatment utilization in academic centres in the Middle East

Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Alroughani R., et al.

36. Therapeutic lag in relapsing multiple sclerosis

Roos I., Frascoli F., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., et al.

37. Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

De Brouwer E., Peeters L., Becker T., Altintas A., Soysal A., Van Wijmeersch B., et al.

38. Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up

Boz C., Terzi M., Ozakbas S., Yuceyar N., Efendi H., Balci B. P., et al.

39. Aggressive form of multiple sclerosis can be predicted early after disease onset

Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.

40. Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data

Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.

41. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

Sharmin S., Lefort M., Andersen J., Horakova D., Havrdova E. K., Alroughani R., et al.

42. Multiple Sclerosis Severity Score (MSSS) helps predict relapses and recovery from disability in patients treated for multiple sclerosis in the MSBase model

Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., Havrdova E. K., et al.

43. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS

Kalincik T., Malpas C. B., Sharmin S., Roos I., Patti F., Butzkueven H., et al.

44. Predicting long-term sustained disability progression in multiple sclerosis

Sharmin S., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., Eichau S., et al.

45. Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Kunchok A., Malpas C., Nytrova P., Havrdova E., Alroughani R., TERZİ M., et al.

71st Annual Meeting of the American-Academy-of-Neurology (AAN), Pennsylvania, Amerika Birleşik Devletleri, 4 - 10 Mayıs 2019, cilt.92, (Özet Bildiri)

46. MULTİPL SKLEROZDA FİNGOLİMOD TEDAVİSİ SONRASI GELİŞEN GEBELİĞİN HASTALIK SEYRİNE OLAN ETKİSİ

TERZİ M., EVİN Ö., BOZ C., ONAR M. K.

MS DAYS V, KYRENIA, 2 - 04 Kasım 2018, ss.15, (Tam Metin Bildiri)

47. Determinants of disability accumulation in secondary-progressive multiple sclerosis

Lizak N., Malpas C., Sharmin S., Havrdova E., Horakova D., Izquierdo G., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.30, (Tam Metin Bildiri)

48. Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form

Eichau S., Spelman T., Izquierdo G., Laffaldano P., OrejaGuevara C., Butzkueven H., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.31, (Tam Metin Bildiri)

49. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry

Spelman T., Havrdova E., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.31, (Tam Metin Bildiri)

50. RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the ’xxRELOMS-T’xx

SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.100, (Özet Bildiri)

51. RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the 'RELOMS-T'

Sevim S., Demirkiran M., Terzi M., Yuceyar A. N., Tasdelen B., Idiman E., et al.

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.174, (Özet Bildiri)

52. Variability in scoring the functional system scores of the expanded disability status scale at clinics from different countries

Hum S., Brown R., Lapierre Y., Fellows L., Mayo N., Havrdova E. K., et al.

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.155-156, (Özet Bildiri)

53. Methylprednisolone concentration in milk and serum during and shortly after IV pulse therapy in patients with MS

Boz C., Ozer B., Terzi M., Karahan S. Z., Sen S., Mavis M., et al.

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.978, (Özet Bildiri)

54. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.

Spelman T., Harvrdova E. K., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., et al.

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.25-26, (Özet Bildiri)

55. Investigation of the Clinical and Morphometric Changes Before and After Acupuncture Treatment in Patients with Bell’s Paralysis

ERTEMOĞLU ÖKSÜZ C., KALAYCIOĞLU A., YILDIRIM A., UZUN Ö., KALKIŞIM Ş. N., BOZ C., et al.

1.Uluslararası Geleneksel ve Tamamlayıcı Tıp Kongresi, 19 - 22 Nisan 2018, (Tam Metin Bildiri)

56. Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry

Kister I., Bacon T., Shaygannejad V., Havrdova E., Alroughani R., TERZİ M., et al.

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)

57. A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., et al.

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)

58. Let's raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the 'RELOMS-T' Study

Sevim S., Demirkiran M., TERZİ M., Yuceyar N., Tasdelen B., İDİMAN E., et al.

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)

59. Susac Syndrome: Clinical Features, Laboratory Testing and Treatment Responses of 3 Cases

Ozmenoglu M., Karahan S. Z., Usta N. C., BOZ C.

10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 Kasım 2017, cilt.24, ss.421, (Özet Bildiri)

60. De Novo Trigeminal Neuralgia Induced by Dalfampridine (4-aminopyridine):3 Cases

Ozmenoglu M., BOZ C., Seker D., Horozoglu H.

10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 Kasım 2017, cilt.24, ss.379, (Özet Bildiri)

61. Multipl Skleroz artık HBS sekonder nedenleri arasında yerini almalı: Bu alanda şimdiye kadar yapılmış en geniş çaplı çalışmanın (Multipl sklerozun huzursuz bacakları-Türkiye) (RELOMS-T)) çarpıcı sonuçları

SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.

53. Ulusal Nöroloji Kongresi, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)

62. MULTİPL SKLEROZDA FAMPRİDİNE TEDAVİSİ SONRASI TRİGEMİNAL NEVRALJİ

TERZİ M., BOZ C., ŞENER M., BEKIR Ö., ŞEN S.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)

63. MULTIPL SKLEROZ’DA MORTALİTE

TERZİ M., BOZ C., KIZILATEŞ G., ŞEN S., BEKIR Ö.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)

64. Susac Syndrome: Clinical features, Laboratory Testing and Treatment Response of 3 cases

ÖZMENOĞLU M., ZENGİN KARAHAN S., CAN USTA N., BOZ C.

10th Congress of the Pan-Asian Committe for Treatment and Research in Multiple Sclerosis, 23 - 25 Kasım 2017, (Tam Metin Bildiri)

65. Ms Tedavisinde Kullanılan İlaçların Kesilme Oranları ve Nedenleri

Çağlar Okumuş A., BOZ C., TERZİ M., ÖZAKBAŞ S., Türkoğlu R., Soysal A., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)

66. Orta ve Doğu Karadeniz Bölgesinde Pediyatrik ve Yetişkin Multipl Skleroz Hastalarının Demografik ve Klinik Özellikleri

Şipal C., Akçaoğlu Y., BOZ C., TERZİ M.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.87, (Özet Bildiri)

67. MULTIPL SKLERODA DİMETİL FUMARAT TEDAVİSİ GERÇEK YAŞAM VERİSİ

TERZİ M., BOZ C., ŞEN S., GÜLER S., ÇİLİNGİR V., ŞENER M.

53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.229, (Özet Bildiri)

68. MULTİPL SKLEROZ’DA NATALİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİSİ

TERZİ M., BOZ C., ÇİLİNGİR V., ŞEN S., ŞENER M., GÜLER S.

53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.229-230, (Özet Bildiri)

69. MULTİPL SKLEROZ HASTALARINDA GLATİRAMER ASETAT TEDAVİSİNİN GÜNLÜK VE HAFTADA 3 KULLANIMI İLAÇ MEMNUNİYETİ

TERZİ M., BOZ C., BİLGE N., ÇİLİNGİR V., BEKIR Ö., BIÇAKCI D., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.230-231, (Özet Bildiri)

70. MS TEDAVİSİNDE KULLANILAN İLAÇLARIN KESİLME ORANLARI VE NEDENLERİ

ÇAĞLAR OKUMUŞ A., BOZ C., TERZİ M., ÖZAKBAŞ S., TÜRKOĞLU R., SOYSAL A., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.293, (Özet Bildiri)

71. MS TEDAVİSİNDE TERİFLUNOMİDE VE FİNGOLUMOD’UN KARŞILAŞTIRMALI ETKİNLİK VERİLERİ

BOZ C., ÖZAKBAŞ S., TERZİ M., TÜRKOĞLU R., SOYSAL A., TUNCER M. A., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.54-55, (Özet Bildiri)

72. MS Tedavisinde Teriflunomide ve Fingolimod’un Karşılaştırmalı Etkinlik Verileri

BOZ C., ÖZAKBAŞ S., TERZİ M., Türkoğlu R., Soysal A., TUNCER M. A., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.54, (Özet Bildiri)

73. MULTİPL SKLEROZDA MORTALİTE

TERZİ M., BOZ C., KIZILATEŞ EVİN G., ŞEN S., BEKİR Ö.

53. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.53, (Özet Bildiri)

74. MULTİPL SKLEROZ ARTIK HBS SEKONDER NEDENLERİ ARASINDA YERİNİ ALMALI!: BU ALANDA ŞİMDİYE KADAR YAPILMIŞ EN GENİŞ ÇAPLI ÇALIŞMANIN [MULTİPL SKLEROZUN HUZURSUZ BACAKLARI-TÜRKİYE (RELOMS-T)] ÇARPICI SONUÇLARI

SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.

53. ULUSAL NÖROLOJİ KONGRE, Türkiye, 24 Kasım 2017 - 30 Ocak 2018, ss.54, (Özet Bildiri)

75. Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis

Kister A., Spelman T., Patti A., duguette A., TROJANO M., Izquierdo G., et al.

MULTIPLE SCLEROSIS JOURNAL, Paris, Fransa, 25 - 28 Ekim 2017, (Özet Bildiri)

76. METHYLPREDNİSOLONE CONCENTRATİONS İN BREAST MİLK AND SERUM İN PATİENT WİTH MULTİPLE SCLEROSİS TREATED IV PULSE METHYLPREDNİSOLONE

BOZ C., TERZİ M., KARAHAN S., ŞEN S., SARAÇ Y., MAVİŞ E.

ECTRIMS 2017, 25 - 28 Ekim 2017, (Özet Bildiri)

77. Prognostic value of MRI activity in treatment failure

Kunchok A. C., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.988-990, (Özet Bildiri)

78. Methylprednisolone concentrations in breast milk and serum in patients with multiple sclerosis treated with IV pulse methylprednisolone

Boz C., Terzi M., Karahan S. Z., Ozbudun B., Sen S., Sarac Y., et al.

79. Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

Jokubaitis V. G., Havrdova E., Horakova D., Izquierdo G., Kalincik T., van der Walt A., et al.

80. Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years

Kalincik T., Spelman T., Jokubaitis V., Horakova D., Havrdova E., Trojano M., et al.

81. Silent lesions on MRI - shifting goal post for treatment decisions in MS

Min M., Lechner-Scott J., Spelman T., Sola P., Granella F., Butzkueven H., et al.

82. Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis

Boz C., Ozakbas S., Terzi M., Turkoglu R., Akman G., Efendi H., et al.

83. The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

Brown J. W. L., Lugaresi A., Horakova D., Havrdova E., Jokubaitis V., Lechner-Scott J., et al.

84. Contribution of inflammation to disability accrual in primary progressive multiple sclerosis

Hughes J., Jokubaitis V., Spelman T., Lugaresi A., Hupperts R., Izquierdo G., et al.

85. Susac syndrome: clinical features, laboratory testing and treatment responses of 20 cases

Karahan S. Z., Boz C., Usta N. C., Saip S., Kale N., Demirkaya S., et al.

86. Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

Merkel B., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.

87. Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Kalincik T., Spelman T., Jokubaitis V., Horakova D., Havrdova E., Izquierdo G., et al.

88. Risk of secondary progressive multiple sclerosis: a longitudinal study

Fambiatos A., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.

89. A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS

Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., et al.

90. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis

Boz C., Terzi M., Karahan S. Z., Sen S., Sarac Y., Mavis M.

3rd Congress of the European-Academy-of-Neurology, Amsterdam, Hollanda, 01 Haziran 2017, cilt.24, ss.490, (Özet Bildiri)

91. Pediatrik başlangıçlı multiple skleroz ile erişkin başlangıçlı multiple sklerozun klinik özelliklerinin karşılaştırılması

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DURGUT B. D., DİLBER B., et al.

19. Ulusal Çocuk Nörolojisi Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)

92. Pediatrik başlangıçlı multipl skleroz ile erişkin başlangıçlı multipl sklerozun klinik özelliklerinin karşılaştırılması.

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., et al.

19. Ulusal Çocuk Nörolojisi Kongresi, Kıbrıs (Kktc), 19 - 23 Nisan 2017, (Özet Bildiri)

93. Spinal anestezi sonrası gelişen unilateral abducens sınır paralizisi

KARAMAN A., GAZİOĞLU S., GÜRSOY M., ALTUNAYOĞLU ÇAKMAK V., BOZ C.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)

94. TEP 147 MS Tedavisinde Teriflunomide in Etkinlik ve Tolerabite Gerçek Yaşam Verileri

BOZ C., TERZİ M., TÜRKOĞLU R., AKMAN G., EFENDİ H., AKÇALI A., et al.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016

95. Wernicke ensefalopatisi: olgu sunumu

GÜRSOY M., AKPINAR R., ALTUNAYOĞLU ÇAKMAK V., BOZ C., GAZİOĞLU S.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)

96. T1-T2 radikülopatiye bağlı horner sendromu olgusu

ŞENER S., ÖZTÜRK S., GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., BOZ C.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)

97. Anti inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosisAuthor s J Lorscheider V Jokubaitis T Spelman G Izquierdo A Lugaresi E Havrdova D Horakova M Trojano P Duquette M Girard A Prat F Grand Maison R Hupperts P Grammond E Pucci C Boz P Sola D Spitaleri J Lechner Scott M Terzi V Van Pesch G Iuliano R Bergamaschi R Fernández Bolaños C Ramo Tello F Granella M E Rio C Oreja Guevara H Butzkueven T Kalincik MSBase Study Group

Lorscheider l., jocubatis v., spelman t., Izquierdo g., lugaresi a., hardova e., et al.

ECTRIMS 2016, 14 - 16 Eylül 2016, (Özet Bildiri)

98. Individual response to disease modifying therapies a global observational cohort studyAuthor s T Kalincik L Sobisek V Jokubaitis T Spelman D Horakova E Havrdova M Trojano G Izquierdo A Lugaresi M Girard A Prat P Duquette P Grammond P Sola R Hupperts F Grand Maison E Pucci C Boz R Alroughani V Van Pesch J Lechner Scott M Terzi R Bergamaschi G Iuliano F Granella D Spitaleri V Shaygannejad C Oreja Guevara M Slee R Ampapa F Verheul P McCombe J Olascoaga M P Amato S Vucic S Hodgkinson C Ramo S Flechter E Cristiano C Rozsa F Moore J L Sanchez Menoyo M L Saladino M Barnett H Butzkueven MSBase Study Group

Kalincik t., Sobisek l., jocubatis v., spelman t., Dana H., Eva H., et al.

ECTRIMS 2016, 13 - 16 Eylül 2016, (Özet Bildiri)

99. Comparison of 5 year treatment outcomes between alemtuzumab versus natalizumab fingolimod and interferon 1a

Kalincik T., Brown j., Robertson R., Willis m., Scolding N., Pearson O., et al.

ECTRIMS 2016, 13 - 16 Eylül 2016, (Özet Bildiri)

100. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Fragoso Y. D., Alroughani R., Barnett M., Brooks J. B., Butzkueven H., Boz C., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.337-338, (Özet Bildiri)

101. Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis

Lorscheider J., Jokubaitis V., Spelman T., Izquierdo G., Lugaresi A., Havrdova E., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.367-369, (Özet Bildiri)

102. Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

Kalincik T., Brown J. W., Robertson N., Willis M., Scolding N., Pearson O., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.829-832, (Özet Bildiri)

103. Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis.

Iaffaldano P., Simone M., Lucisano G., Ghezzi A., Coniglio G., Morra V. B., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.62-63, (Özet Bildiri)

104. Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey

Terzi M., Kurtuncu M., Eraksoy M., Karabudak R., Tuncer A., Altunrende B., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.310, (Özet Bildiri)

105. Long-term disability trajectories in primary progressivs MS patients - a latent class growth analysis.

Signori A., Izquierdo G., Lugaresi A., Hupperts R., Grand'Maison F., Sola P., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.44-46, (Özet Bildiri)

106. Outcomes of pregnancy in neuromyelitis optica patients: turkish multicenter study data

Altintas A., Uygunoglu U., Terzi M., Boz C., Saip S., Koseoglu M., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.405-406, (Özet Bildiri)

107. Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide

Spelman T., Kalincik T., Trojano M., Grand'Maison F., Izquierdo G., Havrdova E., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.602-603, (Özet Bildiri)

108. Individual response to disease modifying therapies: a global observational cohort study

Kalincik T., Sobisek L., Jokubaitis V., Spelman T., Horakova D., Havrdova E., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.358-360, (Özet Bildiri)

109. Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer

Spelman T., Izquierdo G., Lugaresi A., Alroughani R., Duquette P., Boz C., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.600-602, (Özet Bildiri)

110. Prospectively Tracking DiseaseCourse and Treatment Changes in Neuromyelitis Optica Using NMOBase a Global Online Registry Ilya Kister Tamar Bacon Vahid Shaygannejad JyhYung Hor Raed Alroughani Shannon Haas Murat Terzi Cavit Boz Javier Olascoaga Pamela McCombe Yara Fragoso AlessandraLugaresi Patrizia Sola Steve Vucic EugenioPucci Talal Al Harbi Seyed Aidin Sajedi Juan Ignacio Rojas Liliana Patrucco EdgardoCristiano Jose Alberto Suarez MagdaliniTsolaki Bruce Taylor Gerardo Iuliano Paschalis Devranis Mark Marriott HelmutButzkueven

Kister I., bocan t., Shaygannejad v., Yung Hor j., Alroughani r., Shannon h., et al.

aan2016, 12 - 18 Nisan 2016, (Özet Bildiri)

111. Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry.

Kister I., Bacon T., Shaygannejad V., Hor J. Y., Alroughani R., Haas S., et al.

68th Annual Meeting of the American-Academy-of-Neurology (AAN), Vancouver, Kanada, 15 - 21 Nisan 2016, cilt.86, (Özet Bildiri)

112. Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.

Butzkueven H., Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., et al.

8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul, Güney Kore, 19 - 21 Kasım 2015, cilt.22, ss.418-419, (Özet Bildiri)

113. MS te yeni fenotipik patolojik ve klinik sınıflama

BOZ C.

Ulusal Nöroloji kongresi, Türkiye, 29 Kasım - 01 Aralık 2015

114. RRMS HASTALARINDA 12 AYLIK FİNGOLİMOD TEDAVİSİ SONUÇLARI: FİNE ÇALIŞMASI

AKMAN DEMİR G., Türkoğlu R., SAİP S., YÜCEYAR A. N., EFENDİ H., TURAN Ö. F., et al.

51. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 27 Kasım - 03 Aralık 2015, (Özet Bildiri)

115. Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity

Spelman T., Izquierdo G., Alroughani R., Fernandez Bolaos R., Havrdova E., Horaova D., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.237-238, (Özet Bildiri)

116. Defining secondary progressive multiple sclerosis

Lorscheider J., Buzzard K., Jokubaitis V., Spelman T., Havrdova E., Horakova D., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.798-800, (Özet Bildiri)

117. 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

Jokubaitis V. G., Spelman T., Kalincik T., Travaglini D., Paolicelli D., Duquette P., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.100-102, (Özet Bildiri)

118. Lack of association between pulse steroid therapy and bone mineral density in patients with multiple sclerosis

KARAHAN S. C., BOZ C., USTA N. C., KILIC S., Ozmenoglu M., Altunayoglu V., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.773, (Özet Bildiri)

119. Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis

Stewart T., Jokubaitis V., Spelman T., Havrdova E., Horakova D., Trojano M., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.726-728, (Özet Bildiri)

120. Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS

Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., Wiendl H., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.258-259, (Özet Bildiri)

121. Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis

Lizak N., Lugaresi A., Alroughani R., Lechner-Scott J., Slee M., Havrdova E., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.308-310, (Özet Bildiri)

122. Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort: demographic, clinical, laboratory and radiological features

Altintas A., Karabudak R., Balci B. P., Terzi M., Soysal A., Saip S., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.348-349, (Özet Bildiri)

123. Comparison of fingolimod versus interferon beta/glatiramer acetate as second-line therapy in active multiple sclerosis

He A., Spelman T., Jokubaitis V., Lugaresi A., Izquierdo G., Trojano M., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.193, (Özet Bildiri)

124. Evaluation of common criteria of progression of disability in a large observational cohort

Kalincik T., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.62-63, (Özet Bildiri)

125. Independent predictors of time to relapse after CIS in high-risk patients

Spelman T., Meyniel C., Trojano M., Lugaresi A., Izquierdo G., Grand'Maison F., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.54, (Özet Bildiri)

126. NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica

Kister I., Bacon T., Alroughani R., Boz C., Cristiano E., Iuliano G., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.165, (Özet Bildiri)

127. Predictors of disability accrual in multiple sclerosis patients on first-line therapy

Spelman T., Jokubaitis V., Izquierdo G., Duquette P., Grand'Maison F., Grammond P., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.405, (Özet Bildiri)

128. Seasonal variation of relapse rate in MS is latitude-dependent

Spelman T., Gray O., Trojano M., Petersen T., Izquierdo G., Lugaresi A., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.218-219, (Özet Bildiri)

129. Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.195-196, (Özet Bildiri)

130. Rekürrenslerle giden ADEM Guillain Barre Sendromu birlikteliği: Olgu Sunumu

ŞAHİN S., KAMAŞAK T., Baba Ö., CANSU A., BOZ C.

16. Ulusal Çocuk Nöroloji Kongresi, Türkiye, 22 - 27 Haziran 2014, (Özet Bildiri)

131. Head-to-head Comparisons of Interferon Beta and Glatiramer Acetate in Clinical Practice

Butzkueven H., Kalincik T., Jokubaitis V., Izguierdo G., Duquette P., Girard M., et al.

6th Congress of the Pan-Asian-Committee-on-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Kyoto, Japonya, 6 - 08 Kasım 2013, cilt.20, ss.927, (Özet Bildiri)

132. Factors associated with early hospital arrival in acute ischemic stroke patients

Koksal E. K., Gazioglu S., Boz C., Can G., Alioglu Z.

Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.21, ss.353, (Özet Bildiri)

133. Factors associated with early hospital arrival in acute ischemic stroke patients

Koksal E. K., Gazioglu S., Boz C., Can G., Alioglu Z.

Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.261, (Özet Bildiri)

134. Multipl Skleroz hastalarında kişilik özellikleri ve klinik özelliklerle ilişkisi

GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ÖZKORUMAK KARAGÜZEL E., CAN USTA N., BOZ C.

49. Ulusal Nöroloji Kongresi, Trabzon, Türkiye, 15 - 21 Kasım 2013

135. Multipl Skleroz hastalarında kisilik özellikleri ve klinik özelliklerle iliskisi

GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ÖZKORUMAK KARAGÜZEL E., USTA N. C., BOZ C.

49. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 15 - 21 Kasım 2013, ss.108, (Tam Metin Bildiri)

136. Huzursuz bacaklar sendromlu hastaların mizaç ve karakter özellikleri

ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S., ÖZKORUMAK KARAGÜZEL E., USTA N. C., TOPBAŞ M., BOZ C.

14. Ulusal Uyku Tıbbı Kongresi, Muğla, Türkiye, 6 - 10 Ekim 2013, ss.9, (Tam Metin Bildiri)

137. Relapse incidence in women and men throughout the course of multiple sclerosis: an MSBase cohort study

Kalincik T., Vivek V., Jokubaitis V., Lechner-Scott J., Trojano M., Izquierdo G., et al.

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.28-30, (Özet Bildiri)

138. Predictors of 12-month confirmed disability progression after onset of clinically isolated syndrome (CIS) suggestive of multiple sclerosis

Jokubaitis V. G., Spelman T., Trojano M., Izquierdo G., Grand'Maison F., Duquette P., et al.

139. Symptomatology of multiple sclerosis relapses varies in relation to demographic and clinical factors

Kalincik T., Buzzard K., Trojano M., Duquette P., Girard M., Izquierdo G., et al.

140. Head-to-head comparisons of preparations of interferon beta and glatiramer acetate: a series of quasi-randomised MSBase trials

Kalincik T., Trojano M., Izquierdo G., Duquette P., Girard M., Grammond P., et al.

141. Defining secondary progressive multiple sclerosis: is it possible to diagnose early?

Spelman T., Trojano M., Duquette P., Izquierdo G., Lugaresi A., Grammond P., et al.

142. Does switching to fingolimod from natalizumab result in short-term relapse exacerbation?

Jokubaitis V. G., Li V., Kalincik T., Izquierdo G., Hodgkinson S., Alroughani R., et al.

143. Clinical And Radiological Characteristics Of Tumefactive Demyelinating Lesions: Follow-up Study

Altintas A., Petek B., Isik N., Terzi M., Bolukbasi F., Tavsanli M., et al.

5th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Beijing, Çin, 13 - 15 Eylül 2012, cilt.19, ss.656, (Özet Bildiri)

144. PREDICTORS OF POSTPARTUM RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS: RESULTS FROM THE MSBASE REGISTRY

Hughes S. E., Spelman T., Gray O. M., Boz C., Trojano M., McDonnell G. V., et al.

Annual Meeting of the Association-of-British-Neurologists, Brighton, İngiltere, 28 - 31 Mayıs 2012, cilt.83, (Özet Bildiri)

145. EXPOSURE TO INTERFERON-beta THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS

Hughes S., Spelman T., Gray O., Boz C., Trojano M., Zwanikken C., et al.

Annual Meeting of the Association-of-British-Neurologists, Brighton, İngiltere, 28 - 31 Mayıs 2012, cilt.83, (Özet Bildiri)

146. Risk factors of reduced bone mass in patients with multiple sclerosis

Boz C., Karahan S. Z.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.249, (Özet Bildiri)

147. Male MS patients fare worse!

Ribbons K. A., McElduff P., Vetere S., Boz C., Trojano M., Zwanikken C., et al.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.79-80, (Özet Bildiri)

148. Seasonal variation of relapse rate and ultraviolet radiation levels are sinusoidal and their phase-shifted relationship is latitude-dependent

Spelman T., Gray O., Trojano M., Lugaresi A., Izquierdo G., Zwanikken C., et al.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.83-84, (Özet Bildiri)

149. Multiple sklerozda huzursuz bacaklar sendromu

ALTUNAYOĞLU ÇAKMAK V., CANATAN S., GAZİOĞLU S., BOZ C.

47. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 25 Kasım - 01 Aralık 2011, ss.68, (Tam Metin Bildiri)

150. Multiple skleroz hastalarında uykusuzluk ve özellikleri

ALTUNAYOĞLU ÇAKMAK V., CANATAN S., GAZİOĞLU S., BOZ C.

47. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 25 Kasım - 01 Aralık 2011, ss.67, (Tam Metin Bildiri)

151. Predictors of Confirmed Disability Progression after a First Demyelinating Event

Butzkueven H., Spelman T., Izquierdo G., Grand-Maison F., Trojano M., Zwanikken C., et al.

63rd AAN Annual Meeting, Hawaii, Amerika Birleşik Devletleri, 9 - 16 Nisan 2011, cilt.76, (Özet Bildiri)

152. Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study

Eraksoy M., Akman-Demir G., Agan K., Gunal D., Us O., Saip S., et al.

19th World Congress of Neurology, Bangkok, Tayland, 24 - 30 Ekim 2009, cilt.285, (Özet Bildiri)

153. Onset of relapses in multiple sclerosis: the effect of seasonal change in both the northern and southern hemisphere

Gray O., Jolley D., Gibson K., Trojano M., Zwanikken C., Grand'Maison F., et al.

25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Düsseldorf, Almanya, 9 - 12 Eylül 2009, cilt.15, (Özet Bildiri)

154. Temporal Variation of Onset of Relapses in Multiple Sclerosis: Results from the Northern and Southern Hemispheres in the MSBase Registry

Gray O. M., Jolley D., Zwanikken C., Trojano M., Grand-Maison F., Duquette P., et al.

61st Annual Meeting of American-Academy-of-Neurology, Washington, Amerika Birleşik Devletleri, 28 - 29 Nisan 2009, cilt.72, (Özet Bildiri)

155. Temporal variation of onset of relapses in multiple sclerosis is not seasonal: results from the MSBase registry

Gray O. M., Jolley D., Zwanikken C., Trojano M., Grand'Maison F., Duquette P., et al.

1st Congress of Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Kuala-Lumpur, Malezya, 21 - 22 Kasım 2008, cilt.15, ss.137-138, (Özet Bildiri)

156. The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis

Gray O. M., Zwanikken C., Trojano M., Grand'Maison F., Duquette P., Grammond P., et al.

1st Congress of Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Kuala-Lumpur, Malezya, 21 - 22 Kasım 2008, cilt.15, ss.140, (Özet Bildiri)

157. The Multiple Sclerosis Severity Score re-examined: Expanded Disability Status Scale rank stability in the MSBase dataset increases five years after onset of multiple sclerosis

Butzkueven H., Jolley D., Trojano M., Zwanikken C., Maison F. G., Duquette P., et al.

13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Kanada, 17 - 20 Eylül 2008, cilt.14, (Özet Bildiri)

158. Reduced effectiveness of long-term interferon beta treatment on relapses in neutralising antibody-positive multiple sclerosis patients: a Canadian MS clinic-based study

Oger J., Boz C., Devonshire V., Hashimoto S., Hooge J., Kastrukoff L., et al.

23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS, Prague, Çek Cumhuriyeti, 11 - 14 Ekim 2007, cilt.13, (Özet Bildiri)

159. Tumefactive demyelinating disease is immunologically different from multiple sclerosis

Boz C., Gazioglu S., Terzi M.

160. Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.

Butzkueven H., Mechati S., Hoffmann M. W., Arruda W., Boz C., Bacile E., et al.

59th Annual Meeting of the American-Academy-of-Neurology, Massachusetts, Amerika Birleşik Devletleri, 28 Nisan - 05 Mayıs 2007, cilt.68, (Özet Bildiri)

161. Bilateral talamik infaktlarda klinik ve radyolojik bulgular

GAZİOĞLU S., BOZ C., ALTUNAYOĞLU ÇAKMAK V.

42. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 12 - 17 Kasım 2006, ss.169, (Tam Metin Bildiri)

162. Is the current trial definition of confirmed disability progression in multiple sclerosis an accurate measure of permanent disease progression?

Butzkueven H., Mechati S., Hoffmann M., Arruda W. O., Bacile E., Boz C., et al.

22nd Congress of the European-Committee-for-the-Treatment-and-Resarch-in-Multiple-Sclerosis, Madrid, İspanya, 27 - 30 Eylül 2006, cilt.12, (Özet Bildiri)

163. The MSBase Global Web Registry: joining independent local patient databases for multi-centre research

Butzkueven H., Arruda W., Boz C., Chapman J., Cristiano E., Fiol M., et al.

18th World Congress of Neurology, Sydney, Avustralya, 5 - 11 Kasım 2005, cilt.238, (Özet Bildiri)

164. Economic impact of primary headaches in Turkey: a university hospital-based study, part II

Karly N., Zarifoglu M., Ertas M., Saip S., Ozturk V., Bycakcy P., et al.

22nd Congress of the International-Headache-Society, Kyoto, Japonya, 9 - 12 Ekim 2005, cilt.25, ss.951, (Özet Bildiri)

165. The MSBase Global Registry: a web platform for collaborative multiple sclerosis outcomes research

Butzkueven H., Arruda W., Boz C., Chapman J., Cristiano E., Deri N., et al.

21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, Thessaloniki, Yunanistan, 28 Eylül - 01 Ekim 2005, cilt.11, (Özet Bildiri)